For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...

The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging ...

Q. I have a leaky heart valve that may need surgery down the road. Can you tell me about heart-valve surgery in one of your columns? A. First, let’s explain briefly how the heart works.

UVM Medical Center is the only Vermont hospital offering Tricuspid Transcatheter Edge-to-Edge Repair (TEER) This new heart ...

Moderate-to-severe tricuspid regurgitation (TR) has a high prevalence in the general population, 1 and it progressively increases in older individuals, in whom it is close to 4%.

With growth in percutaneous fixes for the valve, surgeons at STS 2025 called for innovation, team-based care, and more data.